Determinants of Health Status and Quality of Life of Patients and Their Parents With Inherited Metabolic Diseases Diagnosed During Childhood and Requiring Restrictive and Specific Diet

Brief Summary

Detailed Description

The study population is a dynamic/open cohort consists of all patients MHMRS diagnosed and supported in one of the six Centers of Reference for Metabolical disease or one of the three Centers of Competence for Hereditary Metabolic Diseases or in the Center of Réference for Hereditary liver Metabolism Diseases since 2000. For each patient, the date of entry into the cohort is the diagnostic date of MHMRS. The study includes all prevalent and incident cases . The evaluations include all data collected by querying patients and their families and medical data collected by the medical team. The data collected concern in one hand explanatory variables characterizing the state of health and quality of life of patients, on the other variables describing the factors considered as potential determinants, namely: * Socio -demographic and socio-economic on the patient and family. * Clinical and therapeutic relative to the patient : age at the time of diagnosis, illness and consequences, type of treatment and diet. * On possible alterations of physical health: overall assessment of the importance of using health professionals and specific description of the various physical health problems. * Psycho- behavioral and cognitive. * Quality of life of patients and their family. * On the patient's relationship with the care system (access to care and satisfaction). The frequency of evaluations is 2 years. The evaluation will be at a consultation in the usual medical monitoring way up conducted in these children, allowing to collect clinical information directly nearby medical teams that support them. The various measurement tools used are: * STAI-C and STAI-Y * BRIEFCOPE and KIDCOPE * GOODMAN questionnaire * FAS questionnaire * WECHSLER scale * VSPA, VSPA-e and VSPA-p * QUALIN * WHOQOL-BREF The project is under the authority of a Steering Committee comprising representatives of all the partners in the project teams. The project is supervised by the Scientific Council of the SFEIM (Société Francaise pour les Erreurs Inées du Métabolisme) and the G2M (Groupement des centres de référence et de compétence des Maladies héréditaires du Métabolisme) which is consulted on the scientific guidance of the project. At the end of a study report will be prepared. It will detail all the decisions inherent in the conduct of the project and the results obtained. This report will be sent to the Ministry of Health under the cover of the Delegation for Clinical Research. The report will form the basis of the adjacent communications will be co-signed by the members of the Steering Committee and will reference the origin of the aid received.

Primary Outcomes